Objectives: Clarithromycin is the key drug in the various treatment regimens of Mycobacterium avium complex (MAC) diseases, and is the only drug for which drug susceptibility has been shown to correlate with clinical response in these diseases. A point mutation at either positions 2058 or 2059 of the 23S rRNA gene has been reported to occur in high-level clarithromycin-resistant isolates. In this study, we examined the correlation between the results from a drug susceptibility test and the mutation of the 23S rRNA gene involved in drug resistance in MAC. Furthermore, we adapted a rapid detection method using amplification refractory mutation system (ARMS)-PCR to identify mutations in the 23S rRNA gene in MAC isolates.
Introduction
Pulmonary Mycobacterium avium complex (MAC) infection is a refractory disease that, unlike tuberculosis, does not respond well to conventional antituberculosis drugs. In 1991, in a randomized clinical trial of MAC infection in AIDS patients, Dautzenberg et al. 1 established the usefulness of clarithromycin, a new macrolide antibiotic. However, clarithromycin has not been recommended for use as a single-drug therapy because its efficacy is low and subsequent resistance will likely develop within a few months if it is used alone. Therefore, multidrug combination therapy including clarithromycin is instead described as a basic therapy for non-tuberculous mycobacterial diseases in the American Thoracic Society (ATS) guidelines. 2 The ATS guidelines report that, in contrast to Mycobacterium tuberculosis, drug susceptibility tests are of little use for the treatment of MAC infection, although clarithromycin is the only drug for which the results of susceptibility testing should be taken into consideration in the treatment of MAC infection. 2 However, the antimicrobial activity of macrolides is pH dependent, and determination by conventional drug susceptibility testing has proved to be less than definitive. 3 As a result, in 2003, the NCCLS, now known as CLSI, established standards for MICs based on differences in pH and methods in drug susceptibility tests, which is referred to as the M-24A method. 3 However, due to the slow growth of MAC isolates, it takes a long time to determine their drug susceptibility using this test after submission of clinical isolates. In addition, a relatively high level of expertise is needed for accurate susceptibility testing. Therefore, a novel, rapid and simple detection method for clarithromycin resistance in clinical microbiology laboratories is necessary for the management of patients with MAC infection.
In the case of macrolide-resistant bacteria, such as Mycoplasma pneumoniae and Helicobacter pylori, point mutations at either positions 2058 or 2059 in domain V of the 23S rRNA gene in the macrolide binding site have been reported to be responsible for macrolide resistance phenotypes. A recent increase in macrolide resistance has become a threat to the treatment of infection caused by these organisms. 4 -6 Similar gene mutations have also been reported in non-tuberculous mycobacteriosis (NTM), including those cases associated with M. avium, Mycobacterium intracellulare, Mycobacterium chelonae, Mycobacterium abscessus and Mycobacterium kansasii.
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However, because many of these studies were conducted before the NCCLS/CLSI methods were established, the correlation between the susceptibility of clarithromycin and gene mutations involved in drug resistance has yet to be clearly defined.
In the present study, we investigated the correlation between the mutations of the 23S rRNA gene involved in drug resistance and the MICs of clarithromycin for MAC isolates. In addition, we developed and evaluated the usefulness of a rapid detection method for clarithromycin resistance using amplification refractory mutation system -PCR (ARMS-PCR), a method for detecting responsible gene mutations.
Materials and methods

Strains
M. avium (GTC00603, derived from M. avium ATCC 25291) and M. intracellulare (ATCC 13950) were used as reference strains.
The clinical isolates used in this study consisted of 134 M. avium strains and 78 M. intracellulare strains isolated from patients diagnosed as having pulmonary MAC infection at the National Hospital Organization, Higashinagoya National Hospital, from 2004 to 2008. In addition, 33 M. avium clinical isolates derived from HIV-positive individuals were provided by the National Center for Global Health and Medicine, formerly called the International Medical Center of Japan. Of note, all clinical isolates were collected from patients regardless of their clinical backgrounds and previous use of antibacterial therapy. Furthermore, only one strain from each patient was analysed in this study. All clinical isolates were identified as M. avium or M. intracellulare by the Cobas Amplicor mycobacterium test (Roche Diagnostic Systems, Inc., Basel, Switzerland).
14 After the MAC isolates had been cultured at 378C in 5 mL of Middlebrook 7H9 liquid medium supplemented with 10% oleic acid/albumin/dextrose/ catalase enrichment for 1-3 weeks, 5 mL was transferred to Mycobroth liquid medium (Kyokuto Pharmaceuticals Industrial Co., Ltd, Tokyo, Japan).
Drug susceptibility tests
BrothMIC NTM (Kyokuto Pharmaceutical Industrial Co., Ltd) was used to determine clarithromycin susceptibility of the MAC strains at pH 7.4, according to the manufacturer's instructions for this antimicrobial agent; this procedure is in compliance with NCCLS/CLSI methods. 15 Based on the criteria described in M24-A of the NCCLS/CLSI methods, strains with an MIC of clarithromycin ≤8 mg/L at pH 7.4 were considered susceptible to clarithromycin and those with an MIC ≥32 mg/L at this pH were considered resistant to clarithromycin.
Sequence analysis of DNA corresponding to domain V of 23S rRNA DNA from the 26 clarithromycin-resistant and 219 clarithromycinsusceptible strains (as determined by the drug susceptibility test) was extracted using an InstaGene Matrix (Bio-Rad Laboratories, Hercules, CA, USA) according to the manufacturer's instructions. PCR was performed to amplify the region corresponding to domain V of the 23S rRNA gene according to the method described by Jamal et al. 9 The PCR mixture (50 mL) was composed of 2 mL of DNA solution, 1 U of AmpliTaq Gold DNA polymerase (Applied Biosystems, Foster City, CA, USA), 5 mL of 2 mM deoxynucleoside triphosphate mixture, 5 mL of 10× PCR buffer and 1 mL of each primer (23SF I, TTTAAGCCCCAGTAAACGGC; and 23SR III, GTCCAGGTTGAGGGAACCTT) at 25 mM. The reactions were carried out using a GeneAmp 9700 PCR system (Applied Biosystems). The PCR conditions were as follows: 1 cycle of 958C for 10 min; 35 cycles of 948C for 1 min, 558C for 1 min and 728C for 1 min; and 1 cycle of 728C for 7 min. The PCR products were electrophoresed with the TrackIt 50 bp DNA ladder (Invitrogen, San Diego, CA, USA) in a 2% agarose gel (E-gel; Invitrogen). The resulting PCR products were purified using a GenElute PCR DNA purification kit (Sigma-Aldrich, St Louis, MO, USA), and direct sequencing analysis was performed using the same primers as those used for PCR. The resulting nucleotide sequences were compared with the genomic sequence data for M. avium strain 104, a reference strain (GenBank accession number NC008595). Alignment of the nucleotide sequences was performed using CLC Sequence Viewer 4.6.2. (CLC Bio, Tokyo, Japan).
ARMS -PCR
DNA from the 26 clarithromycin-resistant and 219 clarithromycinsusceptible strains (as determined by the drug susceptibility test) was extracted using InstaGene Matrix (Bio-Rad Laboratories) according to the manufacturer's instructions. Primers (mismatchclarithromycin-f1 to mismatchclarithromycin-f4 and mismatchclarithromycin-r1) were designed using Primer3 software (http://primer3.sourceforge.net/webif. php) based on the nucleotide sequence data for 23S rRNA in M. avium strain 104 (GenBank accession number NC008595) ( . The reaction mixtures were prepared by adding the following to 1 mL of DNA solution: 0.5 mL of each primer at 25 mM; 1 U of AmpliTaq Gold DNA Polymerase (5 U/mL) (Applied Biosystems); 2.5 mL of 2 mM dNTP mixture; 2.5 mL of 10× PCR buffer; and sterile purified water for a total volume of 25 mL. The reactions were carried out using a GeneAmp 9700 PCR system (Applied Biosystems).
Shuttle PCR was performed with 708C as the Tm value for the primers. Therefore, PCR conditions were as follows: 1 cycle of 958C for 10 min; 35 cycles of 958C for 10 s, 648C for 30 s; and 1 cycle of 728C for 7 min. The PCR products were electrophoresed with the TrackIt 50 bp DNA ladder (Invitrogen) in a 2% agarose gel (E-gel; Invitrogen).The judgement standard was checked for 462 bp amplification, and if no amplification was observed, samples were not accepted for determining drug resistance genes by AMRS-PCR. When a 462 bp amplification was present, samples were checked for the presence of a 121 bp amplified product using each primer set. When amplification was observed with CWTP, a strain was judged to be wild-type. A strain was judged to be a mutant type at either positions 2058 or 2059 of the domain V of 23S rRNA when PCR gave a 121 bp product together with a 462 bp product using C2058MTP or C2059MTP, respectively. When both of the 462 bp and 121 bp amplification products were observed using CWTP and C2058MTP or CWTP and C2059MTP, the strain was judged to be a mixed type (Figure 1b) .
Investigation of strains of mixed clarithromycin-susceptible and -resistant subpopulations
Strains TH-51, TH-56 and TH-124, which were revealed as mixed type by ARMS-PCR, and strain INT-68, which showed a discrepancy between its MIC and genotype, were further investigated. The strains were cultured at 378C for 1 -3 weeks in 5 mL of Middlebrook 7H9 liquid medium supplemented with 10% oleic acid/albumin/dextrose/catalase enrichment, and were plated onto Middlebrook 7H11C agar (Becton, Dickinson and Company, Tokyo, Japan). Several (8 -24) of the colonies were randomly selected and cultured in Mycobroth liquid medium (Kyokuto Pharmaceuticals). The culture was again subjected to a drug susceptibility test using BrothMIC NTM, sequence analysis of the DNA corresponding to domain V of 23S rRNA and ARMS-PCR as described in the sections above. In addition, a culture in a well containing 32 mg/L clarithromycin after drug susceptibility tests was mixed with 1 mL of 0.9% saline, followed by centrifugation. Recovered cell pellets were subsequently cultured in Mycobroth liquid medium (Kyokuto Pharmaceuticals) and were then subjected to sequence analysis of the DNA corresponding to domain V of 23S rRNA and ARMS-PCR.
Statistical analysis
Sensitivity [true positive/(true positive+false negative)] and specificity [true negative/(true negative+false positive)] were calculated to assess the performance of both sequence analysis and ARMS-PCR.
Results
Clarithromycin susceptibility tests
As shown in Figure 2 , the results of the clarithromycin susceptibility tests using BrothMIC NTM from 245 clinical isolates showed a bimodal distribution, representing two different populations in terms of the MIC. One population included 26 clarithromycinresistant strains, which exhibited MICs ≥32 mg/L and the other included 219 clarithromycin-susceptible strains, which exhibited MICs ≤8 mg/L. The former clarithromycin-resistant strains consisted of 14 clinical isolates of M. avium from HIV-negative pulmonary MAC patients, 4 isolates of M. avium from HIV-positive patients and 8 isolates of M. intracellulare from HIV-negative pulmonary MAC patients.
Sequence analysis of DNA corresponding to domain V of 23S rRNA
We then subjected the 219 clarithromycin-susceptible strains and the 26 clarithromycin-resistant strains to sequence analysis of DNA corresponding to domain V of 23S rRNA. As shown in Table 2 , we found that all of these susceptible strains were Rapid detection of clarithromycin resistance in M. avium complex 725 JAC wild-type. In contrast, 24 of the 26 resistant strains were of the mutant type; 21 strains had a mutation at position 2058 and three had a mutation at position 2059. One strain, TH-51, was also determined to be clarithromycin resistant, but the sequence at position 2058 was difficult to determine (A N). Furthermore, another strain, INT-68, was found to be clarithromycin resistant, but had no mutation at either of these positions. Thus, the sensitivity of this analysis was calculated to be 92.3% (24/26) and the specificity was 100% (219/219). These results are shown in Table 3 .
Investigation of strains that showed a discrepancy between the drug susceptibility test and DNA sequence As mentioned above, the two strains TH-51 and INT-68 showed discrepancies between the results from the drug susceptibility test and the DNA sequencing analysis. The M. avium isolate TH-51 was resistant according to the drug susceptibility test using BrothMIC NTM, but the nucleotide at position 2058 was indeterminate with sequence analysis of the 23S rRNA gene. TH-51 was subcultured in liquid medium and was subsequently plated on Middlebrook 7H11C agar. From the resulting colonies, 10 isolates were then randomly selected and analysed. One of these isolates was contaminated during culture and was omitted from further analyses. Out of the other nine isolates, three were found to be susceptible and six were resistant according to the drug susceptibility test. One of the six resistant isolates was found to have no mutations at positions 2058 and 2059 according to sequence analysis of the 23S rRNA gene (TH-51 subcultured isolate no. 8). Thus, this isolate was once again subcultured and plated on Middlebrook 7H11C agar plate, and eight of the resulting colonies were randomly selected. Among the eight isolates, three were clarithromycin susceptible and exhibited no mutations, while the other five were clarithromycin resistant and had an A G mutation at position 2058. These results showed that M. avium strain TH-51 was a mixture of both a susceptible subpopulation with no mutation and a resistant subpopulation with an A G mutation at position 2058; these results are shown in Table 4 .
The other isolate that revealed an apparent discrepancy, M. intracellulare strain INT-68, was found to be clarithromycin resistant in the drug susceptibility test and had no mutation according to sequence analysis of the 23S rRNA gene. Thus, this isolate was also subcultured and smeared on Middlebrook 7H11C agar. Ten of the resulting colonies were randomly selected for analysis. As shown in Table 4 , all of these isolates were determined to be clarithromycin-susceptible according to drug susceptibility tests and were found to have no mutations according to sequence analysis. Moreover, bacteria were recovered from liquid culture medium containing 32 mg/L clarithromycin in the well of a BrothMIC NTM plate, and sequence analysis revealed an A G point mutation at position 2058. These results showed that M. intracellulare strain INT-68 was a mixture of both susceptible and resistant subpopulations, the latter of which was relatively small in proportion. Inagaki et al.
Comparison of ARMS -PCR and sequence analysis
Comparison of the results from ARMS -PCR, sequence analysis and clarithromycin susceptibility tests for M. avium isolates and M. intracellulare is shown in Table 2 . All 462 bp amplification products were positive. All susceptible strains of M. avium and M. intracellulare yielded 121 bp amplification products with CWTP, which was consistent with the results of sequence analysis. We observed amplification with C2058MTP in 20 of the 26 resistant strains, which were therefore judged to be 2058 mutant-type strains. Furthermore, amplification with C2059MTP was observed in 2 of the 26 strains, which were therefore judged to be 2059 mutant-type strains, which was consistent with sequence analysis results. Based on these results, the sensitivity was 84.6% (22/26) and the specificity was 100% (219/219) for ARMS -PCR. These results are shown in Table 3 .
Moreover, the discrepancies between the two analyses were also seen in two M. avium strains, TH-56 and TH-124. For TH-56, sequence analysis showed this strain had an A G mutation at position 2058 whereas ARMS -PCR showed amplification of the two products not only with C2058MTP and C2059MTP, but also with CWTP. Therefore, TH-56 was cultured in liquid medium and was subsequently plated onto Middlebrook 7H11C agar. Twenty-four colonies were randomly selected from the resulting colonies and were again subjected to both analyses, which revealed that all were indeed 2058 mutant type according to ARMS -PCR and had an A G mutation at position 2058 according to sequence analysis. These results are shown in Table 4 . Further investigation using isolates recovered from liquid culture medium containing 32 mg/L clarithromycin in the well of a BrothMIC NTM plate gave the same results. Therefore, these analyses failed to confirm that TH-56 was a mixture of different genotypes.
Furthermore, sequence analysis showed that the TH-124 strain had an A C mutation at position 2059 whereas ARMS -PCR showed amplification of this product not only with C2059MTP, but also with CWTP. Therefore, TH-124 was also plated on Middlebrook 7H11C agar after subculturing it in liquid medium, and the resulting eight colonies were subjected to further analysis. As shown in Table 4 , one of the eight isolates was found to be wild-type by both sequence analysis and ARMS -PCR whereas the other seven isolates were 2059 mutant type according to both analyses.
Discussion
In this study, we investigated the correlation between the results of drug susceptibility tests for clarithromycin in MAC isolates using BrothMIC NTM and the mutations in the 23S rRNA gene responsible for clarithromycin resistance. In addition, we evaluated the usefulness of a system for rapid detection of clarithromycin resistance using the ARMS -PCR method.
All MAC isolates recovered from patients with pulmonary diseases were collected from the same hospital in Japan. However, these isolates were collected from patients regardless of their clinical backgrounds or previous use of antibacterial therapy. In addition, we analysed only one strain from each patient. Therefore, we consider these isolates to represent at least a typical population of MAC isolates in a Japanese hospital. The MICs of clarithromycin determined by drug susceptibility tests showed a bimodal distribution for clarithromycin-susceptible and -resistant strains in the clinical isolates of both M. avium and M. intracellulare. Similar results involving a bimodal distribution in MICs of clarithromycin have been observed for H. pylori in a previous study. 16 Furthermore, the clarithromycin resistance of H. pylori has been indicated to be associated with mutations of the 23S rRNA gene. Mechanisms for macrolide resistance proposed so far include an efflux pump, mutations at the 23S rRNA binding sites and methylation of the 23S rRNA binding site. In Streptococcus pneumoniae, an efflux pump is reported to be a cause of low-level resistance, while highly resistant strains have methylation at the 23S rRNA binding site. 5, 17 On the other hand, in M. pneumoniae, high-level resistance to clarithromycin has been demonstrated to occur as a result of gene mutations at the 23S rRNA binding site. 5 Based on the bimodal distribution of clarithromycin resistance in MAC isolates, this resistance phenotype appears to be caused by gene mutations or methylation of the binding site in the 23S rRNA gene. Sequence analysis of the DNA that corresponded to domain V of 23S rRNA confirmed point mutations at either positions 2058 or 2059 in most of the MAC isolates found to be resistant according to drug susceptibility tests. Thus, these results indicate a correlation between drug susceptibility and mutations of the 23S rRNA gene.
Because of recent progress in identifying genes associated with drug resistance in many bacteria, it has become possible to predict drug susceptibility by detecting polymorphisms in a variety of bacteria, such as M. tuberculosis and H. pylori. 18 -23 It is also clinically desirable to establish a similar method for rapid detection of the drug susceptibility of MAC, especially for the key drug clarithromycin. The present study focused on the ARMS -PCR method, which detects a point mutation of a responsible gene by identifying the mismatches in PCR primers. In this method, primers are designed to overlap the mutation site at the 3 ′ end. In addition to the mismatch at the 3 ′ end of the primer, another single mismatched base is introduced at a site just upstream of the mutation site, thereby preventing amplification by PCR, which makes annealing of the primers impossible. Compared with ARMS-PCR, allele-specific primer -PCR, in which the mutation site is incorporated at the second position from the 3 ′ end and a mismatched base is incorporated at the third position, has also been reported to have improved specificity. 24, 25 In the present study, because mutations occur at two adjacent nucleotides, primers were designed so that these two sites were positioned at the 3 ′ end. Inosine, which does not affect the Tm value and does not actively bond with the base, was incorporated in the third position from the 3 ′ end as the mismatched base. One of the advantages of using this method for detecting gene mutations is that it does not require specialized expertise or specific equipment, because the procedure is similar to conventional PCR. Furthermore, with the application of highly specific nested PCR or loop-mediated isothermal amplification, it would be possible to directly detect the mutations responsible for drug resistance of target bacteria in the future. 26 -28 By comparing the results from drug susceptibility tests, ARMS -PCR and sequence analysis in this study, we confirmed that all clarithromycin-susceptible strains had no mutations at either positions 2058 or 2059. In contrast, 24 and 22 out of the 26 clarithromycin-resistant strains were determined to be Rapid detection of clarithromycin resistance in M. avium complex 727 JAC mutant type according to sequence analysis and ARMS-PCR, respectively. Consequently, the sensitivity of the sequence and ARMS -PCR analyses were determined to be 92.3% (24/26) and 84.6% (22/26), respectively, and the specificity of both was 100% (219/219). However, when ARMS -PCR was performed with CWTP, C2058MTP or C2059MTP, the sensitivity increased to 96.2% (25/26) . The potential reasons for the discrepancy between drug susceptibility and the sequence or ARMS -PCR analyses may be the involvement of drug resistance mechanisms other than mutations in the 23S rRNA gene, such as an efflux pump, and methylation of 23S rRNA. In three out of the four MAC isolates that gave discrepant results in the present study, the reasons for this discrepancy appeared to be difficulty in the isolation of the MAC isolates, and the presence of mixtures of drug-susceptible and -resistant subpopulations in various proportions as shown by subculture analysis. Yoshida et al. 29 reported that the strain with the higher proportion of DNA amounts is amplified to a greater degree when using molecular methods. Furthermore, Hillemann et al. 30 reported that if the proportion of a drug-resistant subpopulation in an isolate is too small it can hardly be detected by molecular methods whereas classical drug susceptibility testing might give positive results for resistance in these cases. Consequently, accuracy of detection for molecular methods. such as ARMS-PCR and sequence analysis. likely depends on the proportions of the mixture of drug-susceptible and drug-resistant subpopulations present in the samples. In the M. avium strain TH-56, ARMS -PCR gave positive results for wild-type, 2058 mutant type and 2059 mutant type, while sequence analysis showed only A G mutation at position 2058. This discrepancy between ARMS -PCR and sequence analysis might be due to non-specific binding of the primers used in ARMS -PCR, because further subpopulation analysis showed uniform phenotypes in drug resistance and genotypes in both ARMS-PCR and sequence analysis.
The present study confirmed that a correlation exists between drug resistance to clarithromycin in MAC isolates and mutation at positions 2058 and 2059 of the 23S rRNA gene. Our results also showed that clarithromycin resistance could be detected more simply and rapidly using the ARMS -PCR method than by using conventional drug susceptibility testing. Therefore, ARMS -PCR can likely be used for detection of clarithromycin resistance and can contribute to the appropriate management of patients with MAC infections.
